Get started
Author

M. Munoz

143eP Timing, setting and patient-related factors in real-world chemo-immunotherapy for triple-negative breast cancer (TNBC)
2026 · G. Martinelli, A.B. Rodriguez Garcia, et al. · ESMO Open
77P Evolution of intrinsic breast cancer subtypes from primary to metastatic disease
2026 · B. Adamo, F.J. Muñoz i Carrillo, et al. · ESMO Open
Abstract PS1-08-08: monarchE: subgroup analysis of adjuvant abemaciclib + endocrine therapy for HR+, HER2-, high-risk early breast cancer by nodal status
2026 · J. Cortes, S. R. D. Johnston, et al. · Clinical Cancer Research
P009: Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2-, High-risk Early Breast cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-year Efficacy Outcomes
2025 · V. André, N. Harbeck, et al. · The Breast
P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes
2023 · S. Johnston, M. Toi, et al. · The Breast
Works count: 5
Citation count:
H-index:
I10-index:
Year
Topic
Type